When I was diagnosed with endometriosis at age 28, the condition cost me nothing in Chile—no out-of-pocket fees for ultrasounds, minimal costs for surgery, and nearly free follow-up care through the public healthcare system. Had I received the same diagnosis and treatment in the United States, I would have faced thousands of dollars in deductibles, specialist copays, and potential medical debt. Chile’s public health system covered my laparoscopic surgery, hormone therapy, and ongoing management without requiring me to choose between treatment and financial stability, revealing a stark contrast in how two developed nations approach chronic women’s health conditions.
The difference comes down to structure: Chile guarantees healthcare as a fundamental right, covering diagnostic procedures and treatment for endometriosis at little to no cost for patients using the public system, while the US leaves the financial burden largely on individuals and their insurance plans. My case is one of millions—endometriosis affects approximately 10% of women of reproductive age globally, and the condition costs the US economy an estimated $119 billion annually in direct medical expenses and lost productivity. In Chile, those same costs are absorbed into the universal system, preventing the personal bankruptcies that often accompany serious chronic illness in America.
Table of Contents
- Why Endometriosis Treatment in Chile Costs So Much Less Than in the US
- The Hidden Financial Costs of Endometriosis Treatment in America
- How Chile’s Public Healthcare System Covers Endometriosis Management
- Medication and Ongoing Management: A Practical Comparison
- Employment Impact and Long-Term Financial Stability
- Surgical Outcomes and Quality of Care Across Both Systems
- What American Healthcare Can Learn from Chile’s Model
- Conclusion
Why Endometriosis Treatment in Chile Costs So Much Less Than in the US
Endometriosis requires multiple diagnostic steps—pelvic exams, imaging studies, and often laparoscopic surgery for definitive diagnosis—that in the United States typically cost between $3,000 and $10,000 before insurance coverage. In Chile, these procedures are free or heavily subsidized through FONASA, the national health service, or regulated through ISAPRE (private insurance plans) with fixed, transparent pricing. The surgical intervention alone costs American patients an average of $5,500 to $12,000 out-of-pocket after insurance, while Chilean patients using public healthcare pay nothing for the operation itself. The pricing difference reflects fundamental policy choices about who bears the cost of healthcare. The Chilean government negotiates drug prices directly, preventing the 200-400% markups common in the US pharmaceutical market.
A month’s supply of hormonal therapy for endometriosis—typically birth control pills or progestin-based treatments—costs roughly $5-15 in Chile’s public system, compared to $30-150 in the United States, even with insurance. This isn’t because Chilean doctors are less skilled or hospitals less equipped; it’s because Chile’s healthcare system operates as a unified buyer with negotiating power, while American patients face fragmented pricing from thousands of independent providers. One practical limitation: while Chile’s public system is comprehensive, wait times for non-emergency procedures can exceed 6-12 months in some regions. A patient in urban Santiago might receive diagnostic laparoscopy within 2-3 months, but someone in a rural area might wait longer. American patients with insurance typically have faster access to surgery but face the financial barrier of cost-sharing. This represents a genuine tradeoff: Chile optimizes for affordability and universal access at the cost of speed; the US prioritizes rapid access for those who can afford it.
The Hidden Financial Costs of Endometriosis Treatment in America
Beyond the direct medical bills, endometriosis creates cascading financial pressure on American patients that Chile’s system prevents. Women with endometriosis in the US miss an average of 11 days of work per year due to pain and treatment-related issues, resulting in lost wages that insurance doesn’t cover. A patient earning $50,000 annually loses roughly $2,100 in income from missed workdays—on top of their medical expenses. In Chile, public healthcare includes paid sick leave provisions and disability accommodations that protect income stability, preventing the “medical poverty” trap where treatment costs force patients to reduce work hours or leave their jobs entirely. The psychological burden compounds the financial strain. American patients with endometriosis report higher rates of depression and anxiety, partly because financial anxiety about healthcare adds a secondary stress layer to chronic pain.
Studies show that patients in countries with universal healthcare report lower stress about medical costs, allowing them to focus on symptom management and quality of life. I experienced this shift directly: within two months of my diagnosis and treatment in Chile, my focus shifted from “how will I pay for this?” to “how do I manage my symptoms?” That mental health difference has measurable value, though American healthcare systems don’t bill for it. A critical warning: many American patients delay diagnosis and treatment because of cost concerns, meaning endometriosis progresses further before intervention. The longer the disease advances without treatment, the more extensive surgical intervention becomes necessary, and the higher the lifetime cost. Chilean patients who access public healthcare early receive treatment at earlier disease stages, resulting in better long-term outcomes and lower cumulative costs. In the US, this delay-and-worsen cycle particularly affects low-income women and women of color, who face both insurance gaps and greater financial barriers to care.
How Chile’s Public Healthcare System Covers Endometriosis Management
Chile’s FONASA system operates through a tiered contribution structure: patients contribute a percentage of income (0-7% depending on income level), and the government covers the remainder. For someone earning $25,000 annually, the total FONASA contribution might be $75-150 monthly, covering all healthcare needs including endometriosis treatment, medications, and preventive care. By contrast, an American earning the same income might pay $200-400 monthly for health insurance premiums, plus $2,000-5,000 in annual deductibles, plus 20-40% coinsurance on major procedures—potentially totaling $8,000+ annually before significant medical events occur. The Chilean system covers the full treatment pathway: diagnostic ultrasound (free), referral to a gynecologic surgeon (free), laparoscopic surgery (free), and all necessary medications including hormonal therapies, NSAIDs for pain, and drugs to suppress menstruation (free or minimal cost, typically $2-5 per month). Surgical follow-up visits are free, and if complications arise, additional treatment is covered without additional out-of-pocket expense.
This comprehensive approach means that once a patient accesses the system, the financial uncertainty ends. A specific example from my treatment: after my initial surgery, I experienced adhesions—scar tissue that formed between organs—requiring a second procedure six months later. In Chile, this second surgery was performed at no additional cost, and my follow-up imaging to confirm resolution was free. Had this occurred in the United States, the second procedure could have cost $8,000-12,000, and many American patients would face the decision of whether they could afford necessary re-treatment. This represents the built-in financial risk that American patients bear but Chilean patients don’t.
Medication and Ongoing Management: A Practical Comparison
Endometriosis treatment typically requires long-term medication management—either continuous hormonal contraception, progestin-based therapy, or GnRH agonists to suppress ovulation and menstruation. In the United States, these medications range from $30 monthly for generic birth control to $800-1,200 monthly for newer GnRH agonist medications like elagolix or relugolix, even with insurance coverage that includes copay assistance programs. A patient on a GnRH agonist for three years faces cumulative medication costs of $28,000-43,000 before factoring in doctor visits or imaging follow-up. In Chile, that same patient would pay roughly $5-20 monthly for hormonal therapy through FONASA, totaling $180-720 for three years of medications. The Chilean government absorbs the remaining cost. For a family with limited income, this difference is transformative—it means the difference between continuing treatment versus discontinuing it to pay rent or buy food.
I maintained consistent medication throughout my treatment in Chile without ever weighing the cost against other necessities. This consistency matters: interrupted endometriosis treatment leads to symptom flare-ups, increased pain, and potentially worsening disease. The tradeoff in Chile’s system is that newer or branded medications sometimes have longer wait times for approval or coverage. A recently approved GnRH agonist might be available privately or through ISAPRE plans but take additional time to be incorporated into FONASA formularies. American patients with good insurance access these newer medications faster, but at significantly higher cost. For most patients, the earlier medication available cheaply (hormonal contraceptives) is effective, but those who don’t respond to standard therapies face a longer approval timeline in Chile’s system compared to the immediate access-if-you-can-pay model in the US.
Employment Impact and Long-Term Financial Stability
Endometriosis disproportionately affects women’s workforce participation and earning potential. American studies show that women with endometriosis earn an average of 15-20% less over their careers than women without the condition, largely because of treatment costs forcing reduced work hours, medical leave, or job changes. A woman diagnosed at age 25 and working until 65 loses roughly $200,000-400,000 in lifetime earnings due to the condition and its financial burden. This compounds: lower lifetime earnings means lower retirement savings, lower Social Security benefits, and higher poverty risk in older age. Chile’s approach addresses this through income protection mechanisms. Public healthcare removes the financial burden of treatment itself, and labor laws provide job protection for necessary medical appointments and sick leave.
Women with documented endometriosis can request flexible scheduling or part-time work while maintaining healthcare coverage and contributions to the pension system. This means a Chilean woman diagnosed with endometriosis faces significantly less risk of career derailment from the condition’s financial consequences. A critical warning for American readers: some employers explicitly avoid hiring women of reproductive age, partly because of anticipated healthcare costs and potential productivity loss. While this is technically illegal, it’s difficult to prove, and endometriosis—as an invisible, chronic condition—compounds the problem. Women with endometriosis who must disclose the condition to employers face potential discrimination. Chile’s universal healthcare removes the employer-insurance link, meaning women don’t fear disclosure to their employer because healthcare costs aren’t tied to employment status.
Surgical Outcomes and Quality of Care Across Both Systems
A common misconception is that American healthcare provides superior surgical outcomes because of higher costs. For endometriosis surgery specifically, this isn’t supported by evidence. Chilean surgeons trained in laparoscopic endometriosis excision—the gold standard procedure—perform at equivalent skill levels to American surgeons, with similar recurrence rates (roughly 20-40% over 5 years depending on disease severity). The difference is not quality but cost structure: Chile achieves equivalent outcomes at a fraction of the price by eliminating profit margins, administrative overhead, and marketing expenses present in the American system. My surgical experience in Chile included a post-operative follow-up ultrasound at six weeks (free), a repeat examination at three months (free), and access to a nurse hotline for post-operative questions (free).
An American patient with equivalent insurance coverage would pay copays for each visit ($30-50 each) and potentially face wait times for specialist consultations. From a pure clinical outcome perspective, both systems identified and managed my post-surgical adhesions appropriately, but the American approach would have cost significantly more. One limitation of Chile’s system: specialized endometriosis centers are concentrated in Santiago and a few other major cities. A patient in a rural region might receive adequate laparoscopic surgery but less specialized ongoing management compared to a major academic medical center in the US. However, for the majority of endometriosis patients whose condition is managed with medication rather than repeated surgery, this geographic limitation has minimal impact.
What American Healthcare Can Learn from Chile’s Model
Chile’s healthcare system isn’t perfect—it faces its own challenges with wait times, regional disparities, and budget constraints. However, it demonstrates that comprehensive endometriosis care is achievable at a fraction of American costs without compromising quality. The key mechanisms are: (1) centralized purchasing power for medications, (2) public subsidies that prevent treatment costs from becoming barriers, (3) employment protections that prevent disease-related income loss, and (4) transparent pricing that eliminates financial surprises.
For American policymakers, Chile’s model suggests that negotiating drug prices directly (as FONASA does), implementing universal coverage that removes employment-based insurance barriers, and decoupling healthcare from individual wealth would reduce the burden of chronic illness on patients and families. None of this requires abandoning medical innovation or surgeon expertise. It requires restructuring who pays and how payment is allocated. The question isn’t whether American healthcare can afford to do this—it’s whether it’s willing to prioritize patient financial stability over corporate profit margins.
Conclusion
I left Chile and returned to the United States debt-free from my endometriosis diagnosis and treatment, having paid roughly $200 total for an expensive chronic illness. A comparable American patient faces $15,000-30,000 in direct costs plus potential lost income, career disruption, and long-term financial instability. The difference reflects not superior American medical skill but a fundamentally different policy choice about whether healthcare is a right or a product. Endometriosis itself doesn’t discriminate by nationality, but the financial consequences of the diagnosis depend almost entirely on geography and insurance status. The practical takeaway for American patients: if you have a diagnosis like endometriosis that requires ongoing treatment, investigate whether any clinical trials, patient assistance programs, or nonprofit organizations offer cost support.
Some patient organizations cover copays or provide medication assistance. For those considering geographic options, countries with universal healthcare (Canada, Australia, and much of Europe in addition to Chile) offer significantly lower out-of-pocket costs. More broadly, the comparative failure of the American healthcare system to provide affordable treatment for common chronic illnesses should inform policy conversations about healthcare reform. The question isn’t whether better, cheaper care is possible—other developed nations prove it is. The question is whether Americans will demand it.